Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China

作者：Gang Wang, Juan‐Juan Qin, Weixia Nong, Ding Ma, Cheng Wang, Hui Yu, Siqi Tang, Mei Chen, Jing Gao, Tianyi Gao, Ling Li, Ke Hu, Peigang Yang, Qingqing Qiu, Song Qu · 发表于：ESMO Open · 年份：2025 · DOI：10.1016/j.esmoop.2025.105763 · 被引用次数：5 · 研究领域：Head and Neck Cancer Studies、Cancer Immunotherapy and Biomarkers、Radiomics and Machine Learning in Medical Imaging

INTRODUCTION: This study aims to establish a multidisciplinary consensus on the treatment of nasopharyngeal carcinoma (NPC) in China, with a particular focus on the guidelines for the use of immune checkpoint inhibitors (ICIs) to ensure scientific and rational treatment protocols. METHODS: The consensus was formulated based on the 'guidelines for the diagnosis and treatment of NPC (2024 edition)' issued by the Chinese Society of Clinical Oncology. The Delphi method was used to collect and consolidate expert opinions. Through repeated solicitation and integration of expert opinions, an expert consensus on combined ICI therapy for NPC was ultimately reached. Additionally, a literature review approach was used to facilitate consensus building. RESULTS: The consensus encompasses the current status of NPC diagnosis and treatment, synthesizing existing clinical evidence to deeply discuss major clinical issues. The primary focus of the consensus is on the clinical practice principles and methods of combinatory ICI therapy. It provides guidelines for patient selection, treatment protocols, and management of adverse events in clinical practice. The consensus emphasizes that multidisciplinary collaboration can further enhance the treatment outcomes and quality of life for NPC patients. Future research needs to continue exploring optimized treatment protocols and predictive biomarkers to achieve more precise personalized therapy. CONCLUSION: The consensus underscores the role of ICIs in...